SIGA Technologies, Inc. SIGA R2K

Q: What is the current share price of SIGA Technologies, Inc. (SIGA)?

As of 2026-07-15 16:51 PDT, SIGA Technologies, Inc. (SIGA) trades at $3.56 on NasdaqGM. Its 52-week range is $3.42 to $8.39.

Q: What is the market capitalisation of SIGA?

SIGA Technologies, Inc. (SIGA) has a market capitalisation of $255.34M on NasdaqGM.

Q: What is the P/E ratio of SIGA?

SIGA trades at a trailing price-to-earnings (P/E) ratio of 12.71. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.64.

Q: What is the return on equity (ROE) of SIGA?

SIGA has a return on equity (ROE) of 11.00%. Its return on capital employed (ROCE) is 11.76%.

Q: Is SIGA a good stock to buy?

This page provides a data-driven analysis of SIGA Technologies, Inc. (SIGA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.siga.com

Company Profile ↓

$3.56

-41.34% 1Y

Mkt Cap$255.34M

P/E12.71

P/B1.64

52W High$8.39

52W Low$3.42

Book Value$2.11

EPS (TTM)$0.28

Company Overview

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 22.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 12.7, below the sector median of 25.9.

Healthy Margins

Maintains a net profit margin of 21.6%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.40.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $94.57M (-31.8% YoY); net profit $23.28M.
Trailing 12 Months Year-on-year growth — revenue -11.3%, earnings -60.7%.
5-Year Trend Long-term compounding — revenue CAGR 22.7%, profit CAGR -16.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	22.71%
1 Year:	-11.30%

Compounded Profit Growth

5 Years:	-16.20%
1 Year:	-60.69%

Stock Price Performance

1 Year:	-41.34%
6 Months:	-38.93%
3 Months:	-22.27%
1 Month:	-17.59%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 3% of range

$3.42 $8.39

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)36.01 · Neutral

Price Performance

1M-17.59%

3M-22.27%

6M-38.93%

1Y-41.34%

Valuation vs Sector

P/E of 12.71 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Excellent profit margin of 21.6%.
Compounding revenue at 22.7% over 5 years.
Generates positive free cash flow.

CONS

Earnings shrank at -16.2% CAGR over 5 years.
Trading 57.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

12.71

Industry PE

25.88

Forward P/E

3.39

PEG Ratio

3.37

Book Value

$2.11

Price to Book

1.64

P/S

2.65

EV/EBITDA

4.73

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

22.71%

Profit 5Y

-16.20%

Revenue (YoY)

-11.30%

Earnings (YoY)

-60.69%

Profitability & Returns

ROCE

11.76%

ROE

11.00%

ROA

5.53%

Profit Margin

21.58%

Op Margin

-85.24%

Gross Margin

43.56%

EPS (Latest Qtr)

$-0.05

EPS (TTM)

$0.28

Balance Sheet & Liquidity

Debt/Equity

0.40

Quick Ratio

2.30

Current Ratio

3.25

Debt

$601.02K

Total Assets

$219.39M

Current Assets

Working Capital

Ownership

Promoter Holding

42.80%

Chg in Prom Hold

0.07%

FII / Inst Holding

49.84%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$255.34M

Total Revenue (TTM)

$93.78M

EBITDA

$21.21M

Free Cash Flow

$59.44M

Operating Cash Flow

$27.75M

Shares Outstanding

71.72M

Gross Margin

43.56%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SIGA SIGA Technologies, Inc. R2K	3.56	12.71	$255.34M	0.00%	11.76%	11.00%	22.71%	-16.20%
2	LLY Eli Lilly and Company SPX	1,156.63	41.13	$1.03T	0.60%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	247.02	28.66	$594.63B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.11	119.08	$431.29B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	418.52	31.54	$380.08B	2.18%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	123.61	34.82	$305.29B	2.82%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	168.37	26.10	$261.12B	1.87%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	535.29	29.40	$198.93B	0.35%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	358.32	24.92	$193.39B	2.80%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	1.39M	-	1.75M	2.66M	471.08M	-	10.46M	3.91M	8.11M	-	2.62M	40.35M	44.26M	4.81M	8.65M	4.85M	10.54M	16.67M	72.21M	8.32M	5.88M	9.24M	25.43M	21.81M	10.01M	7.04M	81.12M	2.62M	6.24M
Operating Income	-17.55M	-5.04M	-4.33M	-3.63M	-17.95M	-7.06M	-9.29M	-8.06M	-6.61M	-4.27M	-4.06M	-5.65M	-4.87M	-4.54M	-3.71M	368.88M	-5.54M	2.19M	-1.71M	660.58K	-3.47M	-4.00M	28.80M	32.90M	-1.99M	1.10K	-2.94M	-1.44M	3.07M	42.87M	-2.11M	-4.64M	-1.31M	11.28M	1.08M	542.09K	-2.26M	45.68M	-10.22M	-5.32M
Net Income	-19.06M	-7.15M	-6.57M	-5.63M	-20.09M	-10.45M	-9.57M	-9.24M	-10.44M	-8.62M	-7.50M	-9.82M	-10.30M	-11.58M	-7.05M	388.05M	52.39M	1.63M	-3.16M	-1.21M	-4.50M	-8.90M	20.89M	24.19M	-812.11K	169.20K	-3.11M	-361.05K	2.04M	33.04M	-918.25K	-2.88M	-393.07K	10.28M	1.83M	1.34M	-408.22K	35.48M	-6.37M	-3.45M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.46	-0.15	-0.09	4.71	0.65	-0.02	-0.05	-0.03	-0.06	-0.11	0.26	0.31	-0.02	0.00	-0.04	-0.01	0.03	0.45	-0.01	-0.04	-0.01	0.14	0.03	0.02	-0.01	0.49	-0.09	-0.05
R&D Expense	2.90M	2.81M	2.96M	2.43M	4.93M	2.54M	2.95M	6.07M	8.16M	6.36M	5.07M	2.47M	2.78M	3.01M	3.31M	3.72M	2.97M	4.00M	2.04M	3.34M	3.92M	3.15M	2.71M	2.07M	2.30M	2.26M	3.24M	3.55M	6.84M	5.73M	5.05M	5.12M	3.65M	3.05M	2.89M	3.02M	3.46M	4.40M	7.05M	3.95M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	14.99M	12.27M	477.05M	26.74M	124.96M	133.67M	110.78M	139.92M	138.72M	94.57M
Operating Income	-11.88M	-12.72M	-31.38M	-22.54M	-23.52M	-209.67M	-30.95M	-31.01M	-18.85M	355.10M	-2.32M	84.50M	89.09M	42.70M	83.62M	69.98M	23.70M
Net Income	-19.40M	-28.20M	29.10M	-14.06M	-17.18M	-265.46M	-39.45M	-39.70M	-36.24M	421.81M	-7.24M	56.34M	69.45M	33.90M	68.07M	59.21M	23.28M
Diluted EPS	-0.52	-0.62	0.09	-0.27	-0.33	-4.97	-0.73	-0.69	-0.46	5.18	-0.15	0.71	0.91	0.46	0.95	0.82	0.32
R&D Expense	17.42M	22.66M	18.37M	18.21M	13.79M	10.71M	13.13M	19.71M	16.68M	13.02M	13.30M	10.94M	9.94M	22.53M	16.43M	12.31M	19.96M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	27.03M	90.38M	105.84M	193.82M	160.73M	185.73M	160.98M	144.67M	203.44M	198.57M	149.83M	214.73M	195.04M	254.35M	244.34M	219.47M
Total Equity	1.36K	-12.91M	12.07M	40.77M	28.24M	16.98M	-246.50M	-284.43M	-287.42M	-323.14M	102.91M	97.78M	129.79M	174.31M	170.16M	196.86M	215.80M	198.82M
Cash & Equivalents	2.32M	6.33M	6.33M	49.26M	32.02M	91.31M	99.71M	112.71M	28.70M	19.86M	100.65M	65.25M	117.89M	103.14M	98.79M	150.15M	155.40M	154.97M
Long Term Debt	-	-	-	0	3.96M	1.99M	0	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	14.96M	48.69M	77.59M	176.85M	407.23M	470.16M	448.40M	467.81M	100.53M	100.78M	20.04M	40.41M	24.88M	57.49M	28.53M	20.65M
Current Liabilities	-	-	4.26M	6.92M	15.76M	12.19M	7.46M	7.33M	7.10M	6.81M	11.34M	91.74M	10.48M	30.49M	21.52M	54.12M	25.33M	17.99M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.47M	-10.83M	25.57M	-20.22M	58.44M	14.18M	11.11M	-116.81M	-18.39M	68.87M	-18.20M	71.52M	11.49M	41.61M	94.80M	48.76M	43.47M
Investing Cash Flow	-5.34M	-10.54M	14.76M	-1.94M	-857.34K	-3.46M	3.89M	1.19M	-100.12K	78.24M	-29.09K	-15.50K	-50.62K	0	-21.69K	-42.45K	-355.01K
Financing Cash Flow	25.99M	13.20M	2.59M	4.92M	1.71M	-2.31M	-2.00M	59.09M	-585.57K	-3.81M	-1.18M	-114.60M	-26.20M	-45.96M	-43.42M	-43.46M	-43.55M
Capital Expenditure	-340.73K	-549.94K	-237.02K	-588.24K	-857.34K	-28.05K	-108.95K	-23.93K	-100.12K	-102.26K	-29.09K	-	-	-	-	-	-
Free Cash Flow	-8.81M	-11.38M	25.34M	-20.81M	57.58M	14.15M	11.00M	-116.84M	-18.49M	68.77M	-18.23M	-	-	-	-	-	-
Share Buybacks	0	0	1.35M	0	-	-	0	0	84.00K	0	0	28.50M	26.02M	13.01M	11.07M	0	0
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	0	0	32.94M	32.14M	42.67M	43.12M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-206.9%	-153.6%	74.4%	-8.7%	67.6%	66.7%	38.5%	59.8%	50.4%	25.1%
Net Margin %	-	-	-	-	-	-	-	-264.9%	-295.3%	88.4%	-27.1%	45.1%	52.0%	30.6%	48.6%	42.7%	24.6%
ROE %	150.2%	-233.6%	71.4%	-49.8%	-101.2%	107.7%	13.9%	13.8%	11.2%	409.9%	-7.4%	43.4%	39.8%	19.9%	34.6%	27.4%	11.7%
ROCE %	-	-55.9%	-37.6%	-25.0%	-12.9%	-136.8%	-17.4%	-20.2%	-13.7%	184.8%	-2.2%	60.6%	48.4%	24.6%	41.8%	32.0%	11.8%

Shareholding Pattern

Insiders

42.80%

Institutions

49.84%

Public Float

87.14%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.32%	3.49M	$12.07M
2	Dimensional Fund Advisors LP	3.34%	2.70M	$9.34M
3	AltraVue Capital, LLC	3.00%	2.43M	$8.40M
4	Vanguard Capital Management LLC	2.12%	1.71M	$5.92M
5	Arrowstreet Capital, Limited Partnership	1.89%	1.53M	$5.27M
6	American Century Companies Inc	1.63%	1.32M	$4.55M
7	Geode Capital Management, LLC	1.63%	1.32M	$4.55M
8	AQR Capital Management, LLC	1.51%	1.22M	$4.21M
9	State Street Corporation	1.25%	1.01M	$3.50M
10	First Wilshire Securities Management Inc	1.10%	890.50K	$3.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SIGA

Google News Fri, 22 May 2026

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOb25yd0Uxd1d0ZUtuNS1kNXFUdTVBS2E3N0hTMjVjNU1UczJuYkpBQkM0SXl6enlaVVowLXh0aXdFVk1xa3A1TW02WjlHdGg3aE5JMHNUa1pDQmM0emp2eUYzTWo1bWRWc0cyX3I0MkdwVjRJNjN0Sk5UQUtsZmlzRVJrckszV09BdllZVG…

Google News hu, 09 Jul 2026

Siga Technologies (NASDAQ:SIGA) Stock Price Down 3.5% - What's Next? - MarketBeat

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNd1FaeW9UMTgwdHpGaWdzNmxKQ2N4ZGJ2WHRjR0pydG1YRjJXbEVMa2Zac1RlYldpdE5idkg4UjNrRjh6YUFOUEZ2Y191cWZoWGJ6eWx3RjMxbVkybGZsYl9hZ0ZWOW5IdkxpZXNXOFJKZ1hhamQ2aW02RGxnMUpJWXdHRzg4bzUtd3dORm…

Google News ue, 10 Mar 2026

SIGA Technologies Inc. Common Stock (SIGA) Stock Price Today & Analysis - Gotrade

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE1EVHl1OVp2X1dKazZQNVZsRnYwLWdWek9MdGVWa0N3Q1c0MGZPaVllZTJhRHNmQzVEVE1MLU5oVmJRS1dPay1adW9HUGxfdUI3REJneHQtbw?oc=5" target="_blank">SIGA Technologies Inc. Common Stock (SIGA) Stock …

Google News hu, 25 Jun 2026

SIGA Technologies Inc Actuals & Estimates (NASDAQ:SIGA) - TradingView

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxONFlFczJ4bmg5d0pvTFZyVkJiSzBsNUdYcjFwTjFPSnFsZ3hNNUlYbHlYa19qcmlwYkVHblVkdW1pd3AwSDhRaV9FR21odUVaOUo3dm9BeWg5b2tzaTYyZ21aeEdTUHN2Z0tidkhTY0tMQWI4bFhNNjE4Zlp3VjZhTXdLR1JvUQ?oc=5" t…

Google News hu, 09 Jul 2026

3 Promising Stocks Estimated To Be Up To 26.7% Below Intrinsic Value - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQZ2lmR3AyRW1XTlBMUEdHV3ZyN2NPTjE2cEVjVzFIU3VRV3RxQnhJNmZCTWR2c0JDQnNRYk9QMUV2eGtKZTRORFBLN0hlaUVoYTY5NGdHalpsSDZ1eDFtd0N1RFFFRVdCcU9LajdVRE9QdHRsQmMxdFpJcDRMRUhYZjRQMDdYRGR3d3dZdT…

Google News hu, 08 Jan 2026

Deep Value Biodefense Pharmaceutical Company – SIGA Technologies Inc (SIGA) - The Acquirer's Multiple

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNMnlZWUNLTWtuTDVnQTVfclVHVVpucUxUSHk4N210OE9WMFY1VFZzRWMzRmhlLXdmZGxwdlJ3eEpjOXJXcFA5Y0xUS1hwcHZaZVhfRldLLVpSZ1VPSHVJMk16WDJTak10Q2lPUjByRlc2WXBTMXh5c1Y3SEZfeWEtVVRrcS1yanl5VlE2SG…

SIGA — Frequently Asked Questions

What is the current share price of SIGA Technologies, Inc. (SIGA)?

As of 2026-07-15 16:51 PDT, SIGA Technologies, Inc. (SIGA) trades at $3.56 on NasdaqGM. Its 52-week range is $3.42 to $8.39.

What is the market capitalisation of SIGA?

SIGA Technologies, Inc. (SIGA) has a market capitalisation of $255.34M on NasdaqGM.

What is the P/E ratio of SIGA?

SIGA trades at a trailing price-to-earnings (P/E) ratio of 12.71. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.64.

What is the return on equity (ROE) of SIGA?

SIGA has a return on equity (ROE) of 11.00%. Its return on capital employed (ROCE) is 11.76%.

Is SIGA a good stock to buy?

This page provides a data-driven analysis of SIGA Technologies, Inc. (SIGA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

SIGA Technologies, Inc. SIGA R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks - Yahoo Finance

Siga Technologies (NASDAQ:SIGA) Stock Price Down 3.5% - What's Next? - MarketBeat

SIGA Technologies Inc. Common Stock (SIGA) Stock Price Today & Analysis - Gotrade

SIGA Technologies Inc Actuals & Estimates (NASDAQ:SIGA) - TradingView

3 Promising Stocks Estimated To Be Up To 26.7% Below Intrinsic Value - simplywall.st

Deep Value Biodefense Pharmaceutical Company – SIGA Technologies Inc (SIGA) - The Acquirer's Multiple

SIGA — Frequently Asked Questions

What is the current share price of SIGA Technologies, Inc. (SIGA)?

What is the market capitalisation of SIGA?

What is the P/E ratio of SIGA?

What is the return on equity (ROE) of SIGA?

Is SIGA a good stock to buy?

Explore More